BOSTON, Oct. 14, 2005 – Plureon Corporation announces that it has entered into an agreement with BD (Becton, Dickinson and Company) in the field of diabetes research and development using Plureon's platform stem cell technology. Under the agreement, BD will sponsor Plureon's research efforts for up to three years and will be responsible for further development of the technology.
Kingsley Taft, partner, and Kevin Lam, associate, of Goodwin Procter represented Plureon in this matter.